AstraZeneca Awaits "Orange Book" Listing For Three Prilosec Patents
AstraZeneca has submitted to FDA three additional patents covering its proton pump inhibitor Prilosec for listing in the "Orange Book."
AstraZeneca has submitted to FDA three additional patents covering its proton pump inhibitor Prilosec for listing in the "Orange Book."